Skip to main content
Fig. 5 | BMC Public Health

Fig. 5

From: Targeting screening and treatment for latent tuberculosis infection towards asylum seekers from high-incidence countries – a model-based cost-effectiveness analysis

Fig. 5

Probabilities of LTBI screening and preventive treatment being cost-effective at different thresholds of willingness to pay per quality-adjusted life year gained. The dashed lines denote the following benchmark thresholds for cost-effectiveness (from left to right): £30,000 (~€34,000) – a threshold recommended by the National Institute for Health and Care Excellence (NICE) in the United Kingdom; €81,300 ($91,447), equivalent to twice the 2020 gross domestic product (GDP) per capita for Germany; ~€87,600 ($100,000) – a threshold that is frequently utilized for health-economic analysis in the United States. *Incidence strata denote strata of asylum seekers by estimated TB incidence in their countries of origin

Back to article page

BMC Public Health

ISSN: 1471-2458

Contact us